Prognostic Contribution of the New Immunoglobulin (Ig) Biomarkers (Freelite™ and Hevylite™) in Waldenstrom’s Macroglobulinemia (WM)

M-C. Kyrtsonis¹,*, E. Kouliris¹,2, D. Maltezas¹, T. Tzounov¹, S. Harding³, E. Kastritis², N. Kafassi⁴, V. Bartzis¹, A. Efthymiou¹, K. Bitsanis¹, M. Gavriatopoulou², E. Terpos², C Kalpadakis¹, M. K. Angelopoulou¹, T. P. Vassilakopoulos¹, A. R. Bradwell⁵, Ph. Beris¹, G. A. Pangalis¹, P. Panayiotidis¹, M. A. Dimopoulos²

¹Haematology Unit of First Dpt of Propaedeutic Internal Medicine and Haematology Clinic, Athens Medical School Greece, Laikon Hospital
²Dpt of Therapeutics Alexandra Hospital, Athens Medical School, Greece
³The Binding Site Group Ltd PO Box 11712 Birmingham, B14 4ZB UK
⁴Dpt of Immunology, Laikon Hospital, Athens
⁵Dpt of Immunity and Infection Medical School University of Birmingham Edgbaston Birmingham, B15 2TT UK

Abstract Clinical utility of serum free light chains (sFLC) and heavy chain (HLC) IgM were assessed, using Freelite and Hevylite assays in 70 WM patients. The result showed that median involved (i) sFLC -kappa and -lambda were 45.6 and 78.3 mg/L respectively, median sFLC (kappa+lambda) was 67.4 mg/L. While, median FLCR (involved/uninvolved FLC ratios) were 2.7 and 6.9 in ikappa- and ilambda-restricted patients respectively. Moreover, increased isFLC, sFLC (kappa+lambda) and FLCR were correlated significantly with shorter time to first treatment (TFT) and adverse survival (OVS). Median ilgM-kappa and ilgM -lambda were 25.4 and 34.8 g/L respectively; median HLCR (involved/uninvolved HLC ratios) were 185.5 and 101.9 in kappa- and lambda-restricted patients respectively. In addition, the increased iHLC and HLCR correlated significantly with shorter TFT. Hence, sFLC and HLC measurements appeared to be both prognostic in WM.

Keywords Waldenstrom’s Macroglobulinemia, IgM Quantification, Freelite™, Hevylite™, Monitoring, Prognosis

1. Introduction

Waldenstrom’s macroglobulinemia (WM) is an indolent B cell lymphoproliferative disease, characterized by lymphoplasmacytic infiltration of the bone marrow (BM), lymph nodes or other organs accompanied by serum monoclonal immunoglobulin IgM production[1-3]. It is classified as a separate entity of the lymphoplasmacytic lymphoma type in the WHO classification[4]. Twenty-five to forty percent of patients are asymptomatic and do not need treatment, at least until disease progression, while the majority presents a wide clinical spectrum including fatigue, hyperviscosity manifestations, lymphadenopathy, organomegaly, recurrent infections, peripheral neuropathy and other, as well as varying laboratory findings such as anemia or other cytopenias, blood lymphocytosis, hypoalbuminemia, autoimmune manifestations, increased β₂-microglobulin (β₂-M) and LDH, polyclonal hyper- or more frequently hypo-gammaglobulinemia, independently of IgM levels[5-8]. As a consequence of disease variability, survival ranges from 60 to 120 months. Symptomatic patients should be treated. Response to treatment is evaluated by the regression of signs and symptoms and the decrease of monoclonal IgM serum levels; serum IgM fluctuations is used for disease monitoring[9]. Thus IgM detection, including quantification by serum protein electrophoresis, densitometry and immunofixation, is mandatory for diagnosis and monitoring of WM patients. The accuracy of the tests depends upon the position of the migrating monoclonal protein, the quantification of which requires skilled personnel[10-12]. Furthermore, user operator error may account for unexpected results particularly at low concentration.

New methods for paraprotein free light and heavy chain quantification were recently developed and manufactured [13]. The serum free light chain assay (sFLC; Freelite™ test, the Binding Site, Birmingham, UK) is a decade old by now.
Using antibodies that bind exclusively to the hidden FLC molecules, it allows sensitive nephelometric quantification of circulating unbound serum kappa and lambda light chains. sFLC measurements as well as the resultant FLC ratio (sFLCR) proved to be of clinical and prognostic utility in plasma cell dyscrasias[13-17] and also in B-cell lymphoproliferative disorders including chronic lymphocytic leukemia[18-20].

The most recent Hevylite™ immunoassay uses antibodies that target unique junctional epitopes between the heavy and light chains of each Ig molecule and determines immunoglobulin heavy chain/light chain (HLC) pairs[10,21]. The serum IgM Hevylite assay has been very recently released on the market; it specifically quantifies IgMkappa and IgMLambda separately allowing the calculation of the deriving ratios (HLCR IgMkappa/IgMLambda and vice versa)[21].

Immunoglobulin (Ig) quantification by Freelite™ and Hevylite™ assays overcome some of the technical bias, while in addition they allow a much closer evaluation of the absolute value of the monoclonal intact and free component. Likewise when, for example, the monoclonal component is IgM-kappa, classical IgM measurements include the monoclonal IgM-kappa along with the remaining polyclonal IgM-kappa and the polyclonal IgM-lambda; Freelite™ measurement quantifies the monoclonal free kappa (monoclonal and polyclonal) light chain and separately the polyclonal free lambda light chain and Hevylite™ assay determines the monoclonal IgM-kappa along with the remaining polyclonal IgM-kappa while the polyclonal IgM-lambda is quantified separately.

In the present study, we evaluated the contribution of the new Ig biomarkers (Freelite™ and Hevylite™) in patients with WM.

2. Materials and Methods

2.1. Patients Selection

Seventy WM patients diagnosed and followed in 2 Hellenic centers were included in the study with their characteristics as shown in Table 1.

They were 33 women and 37 men with a median age 66 years. Forty-four, 28 and 28 were in WM-IPSS[22] stage 1, 2 and 3 respectively. Anemia (Hb < 10 g/L) was present in 29% of the patients, thrombocytopenia (PLT < 140x10^9/L) in 13%, and blood absolute lymphocytosis (Lymphocytes > 4x10^9/L) in 13%. Hypoalbuminemia (serum albumin < 3.5 g/dL) was present in 22% and increased LDH (above normal) in 16%. Twenty-two percent of patients had high levels of β2-M (≥ 5.5 mg/L) while in 43% an extensive BM lymphoplasmacytic infiltration (≥ 50%) was found. Splenomegaly was present in 13% and lymphadenopathy in 17% of our patients. Paraprotein by serum immunofixation were IgM-kappa in 52 patients and IgM-lambda in 18 patients. Median IgM paraprotein level at presentation as routinely determined by nephelometry was 24.55 g/L (range 1.5-110), median IgG 8.83 g/L (range 1.96-47.50) and median IgA 0.93 g/L (range 0.22-10.9).

Fifty-one patients (73%) were or became symptomatic during follow up and received treatment according to the international criteria for treatment initiation. The 19 asymptomatic patients (27%) were only followed. Patients’ median follow-up was 47 months (range 0.5-155 months)

<table>
<thead>
<tr>
<th>Disease Characteristics</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphadenopathy</td>
<td>17</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>13</td>
</tr>
<tr>
<td>Symptomatic</td>
<td>68</td>
</tr>
<tr>
<td>WM-IPSS stage</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>44</td>
</tr>
<tr>
<td>2</td>
<td>28</td>
</tr>
<tr>
<td>3</td>
<td>28</td>
</tr>
<tr>
<td>Hb &lt; 10 g/L</td>
<td>29</td>
</tr>
<tr>
<td>PLT &lt; 140x10^9/L</td>
<td>13</td>
</tr>
<tr>
<td>Lymphocytes &gt; 4x10^9/L</td>
<td>13</td>
</tr>
<tr>
<td>alb &lt; 3.5 g/dL</td>
<td>22</td>
</tr>
<tr>
<td>LDH above normal</td>
<td>16</td>
</tr>
<tr>
<td>B2M ≥ 3.5 mg/L</td>
<td>40</td>
</tr>
<tr>
<td>B2M ≥ 5.5 mg/L</td>
<td>22</td>
</tr>
<tr>
<td>Immunofixation</td>
<td></td>
</tr>
<tr>
<td>IgM kappa</td>
<td>74</td>
</tr>
<tr>
<td>IgMLambda</td>
<td>26</td>
</tr>
</tbody>
</table>

| BM lymphoplasmacytic infiltration (≥ 50%) | 43 |

2.2. Sample Collection and Data Generation

Frozen sera collected from the 70 WM patients at the time of diagnosis and from 120 blood donor healthy individuals (HI) were retrospectively analyzed using polyclonal sheep antibodies (Freelite™ and Hevylite™, Binding Site, UK). HLCs measurements were performed by nephelometry on a Dade Behring BN™II nephelometer at the Binding Site laboratory in Birmingham. sFLCs measurements were also performed on a Dade Behring BN™II nephelometer either at the Binding Site laboratory or at the Laikon’s Immunology laboratory, using Freelite™ assay, according to the manufacturers instructions.

The FLCRs were calculated with the involved sFLC as numerator. The HLCRs were calculated with the involved intact Ig as numerator and the polyclonal intact Ig of the same class as denominator, meaning that the ratio was calculated as IgM-kappa/IgMLambda and IgMLambda/IgM-kappa in IgM-kappa and IgMLambda-patients respectively.

Table 1. Patients’ characteristics

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>70</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex M/F</td>
<td>37/33</td>
</tr>
<tr>
<td>Median age</td>
<td>66 years (range 44-91)</td>
</tr>
<tr>
<td>Median follow-up</td>
<td>47 months</td>
</tr>
</tbody>
</table>

Table 1. Patients’ characteristics
Abnormal FLCR and HLCR were defined as any value above the 95\textsuperscript{th} percentile range of HI. Abnormal polyclonal sFLC was also defined using cut-off values the 95\textsuperscript{th} percentile range of the HI. For kappa-restricted patients, lambda values above 32.1 mg/L were considered as polyclonal sFLC raise and values below 12.7 mg/L as polyclonal sFLC suppression. While, for lambda-restricted patients, kappa values above 14.9 mg/L were taken as polyclonal raise and that below 1.88 mg/L as suppression.

Systemic IgG and IgA hypogammaglobulinemia (IgG-SH and IgA-SH) were defined using our laboratory lower cut-off values as IgG < 7 g/L and as IgA < 0.7 g/L respectively. Immunoparesis of the same class (ISC) was defined as any polyclonal HLC value below the 95\textsuperscript{th} percentile range of HI. Abnormal polyclonal sFLC raise and values below 12.7 mg/L as polyclonal sFLC suppression. While, for lambda-restricted patients, kappa values above 14.9 mg/L were taken as polyclonal sFLC raise and values below 12.7 mg/L as suppression.

Median involved sFLC, sFLC (kappa+lambda) and FLCR values above median correlated significantly with BM infiltration ≥ 50\% (p=0.001; p<0.05) and anemia (p=0.016; p<0.05) respectively.

Table 2. HLs’ and Patients’ results

<table>
<thead>
<tr>
<th></th>
<th>Median</th>
<th>95%-ile range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kappa sFLC (mg/L)</td>
<td>8.85</td>
<td>1.88 - 14.9</td>
</tr>
<tr>
<td>Lambda sFLC (mg/L)</td>
<td>20.5</td>
<td>12.7 - 32.1</td>
</tr>
<tr>
<td>Kappa+Lambda sFLC (mg/L)</td>
<td>30.15</td>
<td>17.5 - 44.5</td>
</tr>
<tr>
<td>Kappa/Lambda FLCR</td>
<td>0.43</td>
<td>0.09 - 0.83</td>
</tr>
<tr>
<td>Lambda/Kappa FLCR</td>
<td>2.34</td>
<td>1.21 – 13.1</td>
</tr>
<tr>
<td>IgM kappa (g/L)</td>
<td>0.63</td>
<td>0.29 -1.82</td>
</tr>
<tr>
<td>IgM lambda (g/L)</td>
<td>0.49</td>
<td>0.17 - 0.94</td>
</tr>
<tr>
<td>IgM kappa/IgM lambda HLCR</td>
<td>1.59</td>
<td>0.96 - 2.30</td>
</tr>
<tr>
<td>IgM lambda /IgM kappa HLCR</td>
<td>0.63</td>
<td>0.43 - 1.04</td>
</tr>
</tbody>
</table>

3.3. Relationship between sFLC, HLC and Corresponding Ratios with Time to First Treatment

Involved sFLC, sFLC (kappa+lambda) and FLCR values above median correlated significantly with time to first
treatment (TFT) (p=0.002; p<0.05, p= 0.002; p<0.05 and p=0.011; p<0.05 respectively)

Involved HLC and HLCR above median correlated with TFT (both p<0.001). “Figures 1A and B” showed TFT according to FLCR and HLCR. Indeed, increased total IgM paraprotein measured by standard methods was also related to TFT (p<0.001). The presence of SH, ISC sFLC polyclonal suppression or raise was not associated with TFT

3.4. Relationship Between sFLC, HLC, Corresponding Ratios and Hypogammaglobulinemia with Overall Survival

Disease variables with an adverse prognostic impact on survival were WM-IPSS stage (p<0.001), high β2M levels (p<0.001), abnormal LDH (p=0.001; p<0.05), the involved sFLC values above median (p=0.003; p<0.05) was shown in Figure 2A and sFLC( kappa+lambda) above median (p=0.002; p<0.05) was also shown in Figure. 2B.

In addition, patients with any type of hypogammaglobulinemia (IgG-SH, IgA-SH or ISC) had a tendency for longer overall survival (OVS) than the ones without hypogammaglobulinemia (p=0.139; p<0.05) as shown in Figure. 2C

In multivariate analysis, high β2M levels (≥ 5.5 mg), abnormal LDH, involved sFLC values above median kept their significance.

4. Discussion

Due to the WM wide range of manifestations and varying phenotype, resembling either a lymphoma or a frank plasma...
cell dyscrasia or even an IgM gammopathy of undetermined origin, the exact paraprotein quantification and sensitive prognostication are needed for improved diagnosis, monitoring and management[3,5].

IgM paraprotein, like any other immunoglobulin (Ig), is composed of two Ig heavy chains and two light chains. It was shown, as already mentioned, that Ig light chains are normally secreted in slight excess[10] and that the amount of the excess may consistently increase and carry prognostic information in monoclonal diseases.

With regard to the contribution of sFLC levels in WM patients at diagnosis, a restricted number of studies reported that they can be increased and in such case, correlate with markers of disease activity, such as increased β2M, anemia [23,24], low serum albumin levels as well as with a shorter time to treatment[25,26]. sFLC levels were also found to constitute a marker of response and of disease progression[23]. We confirmed previous results and showed, in addition, that increased sFLC levels at diagnosis correlated significantly with a shorter overall survival. Intriguingly, sFLC levels were more valuable for monitoring and prognostication than FLCR; this was not observed in multiple myeloma[16,17] and chronic lymphocytic leukemia [27].

In the present study, we also demonstrated that increased HLC-IgM correlated significantly with markers of disease activity such as extensive BM infiltration and low serum albumin levels, while high HLCR values with extensive BM infiltration also and the presence of splenomegaly. A recent study[28] suggested that, in WM, IgM secretion is related to the number of BM infiltrating plasma cells, as evaluated by CD138 staining, a finding in keep with results from our group, showing that bone marrow infiltration by CD138 expressing lymphoplasmacytes in WM strongly correlated with IgM levels[29]. In any case, although paraprotein levels are not considered reflecting tumor burden, an association with the percentage of malignant infiltrating cells has been found. Thus, it is suggested that HLC-IgM and HLCR better reflect tumor burden than IgM as classically determined.

In addition, due to the wide range of clinical manifestations and varying survival of WM, the establishment of prognostic factors is needed. Retrospective studies had highlighted a number of adverse factors for survival in WM, including advanced age, anemia, thrombocytopenia, hypoalbuminemia, elevated serum β2-M, increased serum LDH, high serum IgM concentrations, a poor performance status, the pattern or the percentage of BM infiltration and the presence of lymphadenopathy and organomegaly[6-8, 30-38]. In addition, several investigators have applied and validated in WM[7, 39,40], the staging systems used in similar disorders such as IPI[41] for high grade lymphoma, ISS[42] for multiple myeloma and FLIPI[43] for follicular lymphoma. Five years ago, 7 cooperative research teams designed and successfully applied a scoring system for WM patients requiring therapy, the International Prognostic Scoring System for WaldherrmöG's Macroglobulinemia (ISSWM)[22], that was further validated by others[44,45].

In this study, the adverse prognostic impacts of increased serum β2M, LDH levels and WM-IPSS staging system were observed again, while in addition, monoclonal sFLC and sFLC (kappa+lambda) above median correlated with a shorter overall survival. Recently, the prognostic superiority of the sum of monoclonal and polyclonal sFLC compared to the FLCR was shown in chronic lymphocytic leukemia [19,20], a disease with similarities to WM. Hence, in the present study was found that the sum also apply prognostically for TFT and OVS in WM.

Polyclonal hypogammaglobulinemia is a common finding in WM; however a consistent proportion of patients present normal or even increased uninvolved Igs[7].

In the present study, we found that the presence of hypogammaglobulinemia involving Igs of the same and/or of other classes was in favour of a longer survival, while on the contrary, increased uninvolved Igs was not. This finding is in keep with the observation that in CLL, uninvolved light chain increase confer a worse outcome compared to patients with a normal secretion[19,20]. The finding is intriguing and opens issues on the biologic role of the reactive lymphocytic component in indolent lymphoproliferative disorders. Others unanswered issues on possible suppressive inherent mechanisms, such as TGFβ[46] and others that affect both normal and malignant lymphocytes may contribute in disease control should also be explored. However, others reported on the contrary that low levels of serum IgG and IgA were associated with disease progression[47] and further investigations are needed.

5. Conclusions

Serum FLC measurements appear useful for prognostic purposes, HLCR powerfully predicted time to first treatment and therefore may be useful in diagnostic and prognostic settings, while HLC and HLCR also help for follow-up of WM patients. In addition the Hevylite assay provides information about the amounts of the uninvolved Ig subsets that may reflect biology important mechanisms. Further studies are awaited.

REFERENCES

[3] Pangalis GA, Kyrtonis MC, Kontopidou FN, Siakantaris MP,


Avet-Loiseau H, Mirbahai L, Harousseau JL, “Serum immunoglobulin heavy/light chain ratios are independant risk


[29] Dimitrios Maltezas, Tatiana Tze engos, Nikolitsa Kafassi, Efstathios Koulieris, Vassiliki Bartzis, Maria Dimou, Anna Efthymiou, George Georgiou, Th eodores P. Vassilakopoulos, Maria K. Angelopoulou, Panayiotis Tsafaridis, Panayiotis Papayioti dios, Photis Beris, Marie-Christine Kyrtsonis, “Clinical Impact of Increased Serum Free Light Chains (sFLCs) or their Ratio (FLCR) in WM at diagnosis and during disease course”, Proceeding of the 6th International Workshop on Waldenstrom’s macroglobulinemia, Venice, pp. 105, 2010.


[44] Kastritis E, Kyrtsonis MC, Hadjiiharissi E, Symeonidis A,

